AKTX · Akari Therapeutics Plc · Executive Compensation
$8.24
+0.24 (+3.00%)
At close · Oct 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$18.83M
Shares
2.29M
Volume · Oct 30
45.8K
Avg daily vol (3M)
62.13K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Abizer Gaslightwala | President and Chief Executive Officer | $1,663,603 |
| Torsten Hombeck | Former Interim Chief Financial Officer | $621,955 |
| Samir R. Patel | Former President and Chief Executive Officer | $324,985 |
| Kameel Farag | Interim Chief Financial Officer | $117,435 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | Former President and Chief Executive Officer | $1,401,173 |
| Wendy DiCicco | Former Interim Chief Financial Officer | $860,844 |
| Samir R. Patel | Former President and Chief Executive Officer | $435,767 |
| Torsten Hombeck | Former Interim Chief Financial Officer | $12,500 |
| Kameel Farag | Interim Chief Financial Officer | — |
| Abizer Gaslightwala | President and Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | Former President and Chief Executive Officer | $1,560,141 |
| Wendy DiCicco | Former Interim Chief Financial Officer | $277,664 |
| Torsten Hombeck | Chief Financial Officer | $167,506 |
| Samir R. Patel | President and Chief Executive Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Rachelle Jacques | Former President and Chief Executive Officer | $3,602,599 |
| Torsten Hombeck | Former Chief Financial Officer | $448,745 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kameel Farag | interim Chief Financial Officer | Appointed | 2025-10-23 |
| Torsten Hombeck | Chief Financial Officer | Resigned | 2025-08-29 |
| Abizer Gaslightwala | President and Chief Executive Officer | Appointed | 2025-03-20 |
| Michael Grissinger | the Board | Resigned | 2024-12-18 |
| Abizer Gaslightwala | director of the Board | Appointed | 2024-12-18 |
| Samir R. Patel, M.D. | Chief Executive Officer and principal executive officer | Appointed | 2024-12-18 |
| Torsten Hombeck | Chief Financial Officer | Appointed | 2024-12-16 |
| Samir Patel | Interim Principal Financial Officer and Principal Accounting Officer | Appointed | 2024-12-12 |
| Wendy DiCicco | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Terminated | 2024-12-12 |
| Hoyoung Huh | non-executive chairman of the Akari Board | Appointed | 2024-11-14 |
| Sandip Patel | directors | Appointed | 2024-11-14 |
| Hoyoung Huh | directors | Appointed | 2024-11-14 |
| Donald Williams | directors | Resigned | 2024-11-14 |
| James Neal | directors | Appointed | 2024-11-14 |
| Wa'el Hashad | directors | Resigned | 2024-11-14 |
| Robert Bazemore | director of the Board | Appointed | 2024-09-18 |
| Samir R. Patel, M.D. | Interim President and Chief Executive Officer | Appointed | 2024-06-05 |
| Rachelle Jacques | Board of Directors | Resigned | 2024-05-07 |
| Melissa Bradford-Klug | Chief Operating Officer | Terminated | 2024-05-01 |
| Samir R. Patel, M.D. | Interim President and Chief Executive Officer | Appointed | 2024-05-01 |
| Rachelle Jacques | President and Chief Executive Officer | Resigned | 2024-05-01 |
Leadership
- Abizer Gaslightwala CEO, Board Member
- Samir R. Patel CEO
- Samir R. Patel, M.D. CEO
- Hoyoung Huh Chairman, Board Member
- Kameel Farag CFO
- Samir Patel CFO
- Torsten Hombeck CFO
- James Neal Board Member
- Robert Bazemore Board Member
- Sandip Patel Board Member